iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/39329940/
Glioblastoma Tumor Microenvironment: An Important Modulator for Tumoral Progression and Therapy Resistance - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 5;46(9):9881-9894.
doi: 10.3390/cimb46090588.

Glioblastoma Tumor Microenvironment: An Important Modulator for Tumoral Progression and Therapy Resistance

Ligia Gabriela Tataranu  1   2 , Serban Turliuc  3 , Amira Kamel  2 , Radu Eugen Rizea  1   2 , Anica Dricu  4 , Georgiana-Adeline Staicu  4 , Stefania Carina Baloi  4 , Silvia Mara Baez Rodriguez  2 , Andrada Ioana Maria Manole  2
Affiliations
Review

Glioblastoma Tumor Microenvironment: An Important Modulator for Tumoral Progression and Therapy Resistance

Ligia Gabriela Tataranu et al. Curr Issues Mol Biol. .

Abstract

The race to find an effective treatment for glioblastoma (GBM) remains a critical topic, because of its high aggressivity and impact on survival and the quality of life. Currently, due to GBM's high heterogeneity, the conventional treatment success rate and response to therapy are relatively low, with a median survival rate of less than 20 months. A new point of view can be provided by the comprehension of the tumor microenvironment (TME) in pursuance of the development of new therapeutic strategies to aim for a longer survival rate with an improved quality of life and longer disease-free interval (DFI). The main components of the GBM TME are represented by the extracellular matrix (ECM), glioma cells and glioma stem cells (GSCs), immune cells (microglia, macrophages, neutrophils, lymphocytes), neuronal cells, all of them having dynamic interactions and being able to influence the tumoral growth, progression, and drug resistance thus being a potential therapeutic target. This paper will review the latest research on the GBM TME and the potential therapeutic targets to form an up-to-date strategy.

Keywords: extracellular matrix; glioblastoma; molecular diagnostic; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Glioblastoma Tumor Microenvironment: The GBM TME is complex, with a series of unique features, interactions, and components—the ECM, with glycoproteins, proteoglycans, and glycosaminoglycans (e.g., HA), has an important role in creating a barrier between the GBM TME and the normal tissue, promoting invasiveness; the immune cells (GAMs, TANs, monocytes, tumor-infiltrating lymphocytes), neuronal cells, glial cells, and glioma stem cells; chemokines, hormones, enzymes, EVs, and cell-communicating factors like VEGF, EGFR, and mediators like glutamate, with all of them being involved in creating an hypoxic and immunosuppressive TME that promotes tumoral progression and therapy resistance. The blood–brain barrier is also important in modulating the GBM TME components and can limit tissue drug availability, playing an important role in therapy resistance.
Figure 2
Figure 2
The GBM TME is formed by a heterogeneous cell population represented by glioblastoma cells, macrophages, monocytes, microglia—TAMs, tumor-associated neutrophiles—TANs, dendritic cells, astrocytes, endothelial cells, myeloid-derived suppressor cells MDSCs, who are in a close connection, being linked together by mediators and chemoattraction processes.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfister S.M., Reifenberger G., et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro-Oncology. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed
    1. Park Y.W., Vollmuth P., Foltyn-Dumitru M., Sahm F., Ahn S.S., Chang J.H., Kim S.H. The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 1-Key Points of the Fifth Edition and Summary of Imaging Findings on Adult-Type Diffuse Gliomas. J. Magn. Reson. Imaging. 2023;58:677–689. doi: 10.1002/jmri.28743. - DOI - PubMed
    1. Lathia J.D., Mack S.C., Mulkearns-Hubert E.E., Valentim C.L., Rich J.N. Cancer stem cells in glioblastoma. Genes Dev. 2015;29:1203–1217. doi: 10.1101/gad.261982.115. - DOI - PMC - PubMed
    1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Stupp R., Taillibert S., Kanner A., Read W., Steinberg D., Lhermitte B., Toms S., Idbaih A., Ahluwalia M.S., Fink K., et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs. Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318:2306–2316. doi: 10.1001/jama.2017.18718. - DOI - PMC - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources